Bausch Health Companies Inc. (NYSE:BHC) is one of the 7 Oversold Pharma Stocks to Buy Now. Bank of America raised its price target for Bausch + Lomb to $15, citing higher than expected revenue and projected market growth. BHC reported consolidated sales of $10.27 billion in 2025, up 7% from the previous year.

Despite a strong performance in 2025, BHC ended the fourth quarter with a net loss of $112 million. The Salix sector contributed $693 million in revenue, driven by demand for Xifaxan. BHC is a global pharmaceutical company specializing in eye care, dermatology, gastrointestinal, and branded generic medicines.

Investors see potential in BHC, but believe other AI stocks offer more upside. A free report on the best short-term AI stock is available for those seeking undervalued opportunities. For more investment options, check out 12 Unstoppable Dividend Stocks and Dividend Champions, Contenders, and Challengers list for high-yielding stocks.

Read more at Yahoo Finance: Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook